This suggests that PD-L1 can be used as an independent indicator of CRC prognosis, and PD-L1 and TLR-4 expression are closely related, providing a theoretical basis for the future use of PD-1/PD-L1 inhibitors in combination with TLR agonists (70). The gene discussed is CD274; the disease is colorectal carcinoma.